ENTA relative valueRV

ENANTA PHARMACEUTICALS INC. How this company compares with the rest of its industry group on the figures it reported in its last annual filing.

ENTA's operating margin of -130.7% ranks in the 65th percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.

As of . Source: SEC EDGAR XBRL company facts. Method and limitations.

Against 18 Biotechnology peers

10-K FY to 30 Sept 2025 in USD
MetricENTAPeer medianPercentilen
Revenue FY65.3M USD35.9M USD68th13
Revenue YoYn/an/an/an/a
Gross marginn/an/an/a1
Operating margin-130.7%-242.4%65th12
Net margin-125.4%-247.7%65th12
Return on equity-126.5%-69.4%25th13
P / En/an/an/an/a
1 yearn/an/an/an/a

Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Fiscal periods ending between 2025-09-30 and 2025-12-31. Prices as of 2026-10-02. Every fundamental figure is one full fiscal year from one filing. Nothing is trailing twelve months and nothing is converted between currencies. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above. 0001193125-25-288121

Peer set, 18 companies

IRD, ARCT, AGEN, CCCC, FENC, OBIO, GALT, TTRX, ZURA, PROK, SRZN, RLMD, EDIT, SPRY, OCGN, KYTX, MYGN, ARTV

Left out: RZLT (period gap), SCTX (no annual filing), BNTC (period gap), EIKN (no annual filing), PRTC (period gap), AGMB (no annual filing), VOGX (no annual filing).

What could not be compared

  • 54 The filer did not report this line in the filing used.
  • 23 The denominator is zero or negative, so the ratio has no meaning.
  • 19 The price series does not reach back to the start of this window.
  • 4 Fewer than 5 peers carry a comparable value, so no median, quartile or percentile is published.
  • 4 No annual filing (10-K, 20-F or 40-F) with fiscal-year figures.
  • 3 This company's fiscal year ends more than 200 days from the subject's, so it is a different economic year.
  • 1 The latest close times the filed share count disagrees with the company's market cap by more than a split-sized factor, so price and the filing are not on one share basis.

Free account

Open the relative value desk with a free account

An account turns this page into a research desk: thirty-one metrics over the whole peer set instead of eight, the distribution behind each median, the metric's history against the peer band, an editable peer set, the filing behind every cell, and CSV. The table above stays free.

Create a free accountSign in

Cite this data

Every fundamental figure is the full fiscal year reported on one annual SEC filing (10-K, 20-F or 40-F), named by accession. Peers are the company's industry group: the GICS sub-industry where the company is GICS-classified, otherwise the data vendor's industry label (the two label sets are not merged). A median, quartile or percentile is published only when at least five peers carry a comparable value, and a peer reporting in another currency is excluded from a level rather than converted. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above.

Upstream: SEC EDGAR XBRL company facts

Kresmion, "ENTA relative value, Kresmion", data as of 2025-11-19, https://kresmion.com/tools/relative-value/ENTA. Upstream data: SEC EDGAR XBRL company facts.

Link to this data (HTML):

<a href="https://kresmion.com/tools/relative-value/ENTA">ENTA relative value, Kresmion (Kresmion)</a>